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Background  :  Neuropsychiatric  systemic  lupus  erythematosus  (NPSLE)  shows  some  similarities  to  neuroBehçet's 
disease (NBD) in that both conditions have some analogous clinical features and they are both pathologically associated 
cerebral vasculopathy. This study compared the clinical manifestations, brain MRI findings and prognosis of NPSLE and 
NBD  patients.
Methods : Forty three patients with NPSLE (n = 25) or NBD (n = 18), who were monitored at a single center, were 
enrolled in this study. We retrospectively analyzed the clinical and brain MRI data. The neuropsychiatric manifestations 
were  classified  in  both  groups  according  to  the  new  American  College  of  Rheumatology  nomenclature  for  NPSLE.
Results  : T h e  d i f f u s e  s y m p t o m s  t h a t  i n c l u d e d  m o o d  d i s o r d e r s ,  p s y c h o s i s ,  confusion,  cognitive  dysfunctions, 
generalized  seizures  and  headaches  other  than  migraine  or  cluster  headaches  were  more  commonly  observed  in  the 
NPSLE  patients,  while  the  frequency  of  focal  diseases  such  as  cr a n i a l  n e u r o p a t h y  t e n d e d  t o  b e  h i g h e r  i n  t h e  N B D  
patients. The brain MRI revealed that the NBD patients had more abnormalities in the brain stem than did the NPSLE 
patients.  Most  of  the  patients  improved,  at  least  partially,  after  being  treated  with  glucocorticoid  and/or  immune 
suppressants.  However,  the  disease  course  differed  significantly  between  the  two  groups.  There  were  more  episodic 
cases  in  the  NPSLE  group  of  patients,  while  there  were  more  remittent  cases  in  the  NBD  group  of  patients.
Conclusion  : N P S L E  h a d  a  t e n d e n c y  t o  c a u s e  d i f f u s e  n e u r o p s y c h i a t r i c  m a n i f e s tations,  and  it  has  a  different 
predilection  of  brain  lesions  compared  with  NBD.  The  NBD  patients  showed  a  poorer  outcome  than  did  the  NPSLE 
patients,  suggesting  that  different  therapeutic  strategies  for  the  two  diseases  need  to  be  considered. 
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INTRODUCTION 
Behçet's  disease  is  a  chronic  inflammatory  disease  of  an 
unknown  origin,  and  it  is  characterized  by  the  triad  of  oral 
ulcerations,  genital  ulcerations  and  uveitis.  A  number  of 
additional  features  are  commonly  observed:  these  include 
arthritis,  retinal  and  cutaneous  vasculitis,  deep  vein  thrombosis, 
gastroenteric  disorders  and  neuropsychiatric  involvement
1). 
Among these features, neuropsychiatric involvement is one of the 
most  serious  complications.  The  reported  frequency  of 
neuroBehçet's  disease  (NBD)  in  Behçet's  disease  patients 
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employed  large  subject  populations  have  reported  a  rate  of 
approximately 5%
2, 3). The spectrum of NBD varies and this can 
b e  c l a s s i f i e d  i n t o  t w o  m a j o r  f o r m s .  O n e  f o r m  i s  a t t r i b u t a b l e  t o  
small venous inflammatory disease with focal or multifocal central 
nervous system (CNS) parenchymal involvement, and this form is 
seen in the majority of patients. The other form is caused by a 
cerebral  venous  sinus  thrombosis  with  limited  symptoms,  and 
this form has a better neurological prognosis
4). It is quite rare for 
the  two  types  of  involvement  to  occur  simultaneously  in  the 
same  individual
2, 3).  In  addition,  psychiatric  symptoms  and 
peripheral  nervous  system  (PNS)  involvement  is  rarely  encoun-
tered
4).
Systemic  lupus  erythematosus  (SLE)  is  an  autoimmune 
inflammatory  disease  that  might  lead  to  multi-organ  failure  with 
various  clinical  courses  and  a  variable  prognosis,  and  SLE  is 
tightly  linked  to  the  overproduction  of  a  range  of  autoan-
tibodies
5).  Neuropsychiatric  SLE  (NPSLE),  as  well  as  lupus 
nephritis,  is  a  major  cause  of  morbidity  and  mortality  in  SLE 
patients
6). The prevalence of NPSLE ranges from 20% to 60% of 
SLE patients, whch most likely depends on the different inclusion 
criteria used in the studies
7). The spectrum of NPSLE also varies, 
and this includes neurologic syndromes of the central, peripheral 
and autonomic nervous  system. Psychiatric  syndromes are also 
commonly observed in the SLE patients for whom other causes 
h a v e  b e e n  e x c l u d e d
8). 
In addition to the clinical diversity, the difficulty in defining the 
outcome  measures  and  the  lack  of  a  standard  terminology  are 
considered obstacles for understanding the disease mechanisms 
and  for  evaluating  the  level  of  therapeutic  intervention  in  both 
NBD  and  NPSLE  patients.  The  American  College  of 
Rheumatology  (ACR)  has  recently  formulated  specific  criteria  for 
NPSLE.  The  new  nomenclature  includes  case  definitions, 
reporting standards and the diagnostic testing recommendations 
for  19  different  neuropsychiatric  syndromes
8).  These  definitions 
may  provide  a  reliable  classification  for  recruiting  homogenous 
groups  of  patients  for  designing  randomized  controlled  trials
6).
NPSLE  has  some  similarities  to  NBD  in  that  both  conditions 
have some common clinical features and they are pathologically 
associated  with  cerebral  vasculopathy.  Also,  in  Korea,  SLE  and 
Behçet's  disease  are  the  representative  autoimmune  diseases 
involving the nervous system. Therefore, this study compared the 
clinical characteristics, brain MRI findings and prognosis between 
NPSLE  and  NBD  patients  at  a  single  center.  We  demonstrate 
here  that  NPSLE  has  a  propensity  to  cause  diffuse 
neuropsychiatric  manifestations,  and  it  shows  different  predilec-
tions for brain lesions compared with NBD. Moreover, the poorer 
out c ome  i n  NBD c ompa r e d wi t h NP SLE s ugge s t s  t he  n e e d f or 
different  treatments  strategies  for  the  two  diseases. 
MATERIALS AND METHODS
Patients
T h i s  s t u d y  i n c l u d e d  4 3  p a t i e n t s  w i t h  N P S L E  o r  N B D  a n d  
these  patients  were  monitored  at  Kangnam  St.  Mary's  hospital 
between January 1999 and December 2002. The patients were 
identified from the hospital's automated information system. The 
patients'  information  was  analyzed  by  retrospectively  reviewing 
the data registered at regular intervals for at least 3 months. Of 
the patients who were screened, 25 NPSLE patients fulfilled the 
1 9 8 2  R e v i s e d  C r i t e r i a  f o r  S L E  a s  s e t  f o r t h  b y  t h e  A m e r i c a n  
Rheumatism  Association
9),  and  18  NBD  patients  met  the  1990 
criteria  of  the  International  Study  Group  for  Behçet's  disease
10). 
Three  of  NPSLE  patients  had  antiphospholipid  syndrome  that 
fulfilled  both  the  laboratory  and  clinical  Sapporo  preliminary 
criteria
11).  A  written  informed  consent  was  obtained  from  each 
subject  after  giving  a  complete  explanation  of  the  study  to  the 
subjects.  Three  NPSLE  patients  and  3  NBD  patients  were 
r e f e r r e d  t o  t h i s  c e n t e r  f r o m  l o c a l  c l i n i c s  a s  a  r e s u l t  o f  t h e i r  
uncontrolled  symptoms,  and  their  medical  records  from  those 
clinics  were  thoroughly  reviewed.
Data  collection  and  analysis
The clinical data was comprised of gender, the patient's age 
at  the  time  of  the  neuropsychiatric  event,  the  disease  duration 
prior  to  the  neuropsychiatric  attack,  the  follow-up  duration,  the 
neuropsychiatric  manifestations,  the  type  and  dosage  of  drugs 
and the clinical course. A  team  of rheumatologists, neurological 
and  psychiatric  consultants  evaluated  the  level  of  neuro-
psychiatric  involvement.  Those  patients  with  secondary 
neuropsychiatric  events  that  were  not  directly  related  to  SLE 
were  excluded.  The  neuropsychiatric  manifestations  were 
classified  according  to  the  1999  ACR  Nomenclature  and  Case 
Definitions  for  neuropsychiatric  lupus  syndromes
8),  and  all  the 
enrolled  patients  met  these criteria.  Using this  classification,  the 
presentations were subdivided into one of the following groups; 
diffuse  disease  (including  psychosis,  mood  disorder,  cognitive 
dysfunction,  acute  confusional  states,  headaches  other  than 
migraine  or  cluster  headache,  and  generalized  seizures),  focal 
disease  (migraine  or  cluster  headache,  focal  seizures  and  other 
neuropsychiatric  manifestations)  and  complex  presentations 
(cases  where  both  diffuse  and  focal  neuropsychiatric 
manifestations occurred simultaneously). For making comparison 
with  NPSLE,  the  neuropsychiatric  manifestations  of  NBD  were 
also  classified  with  using  the  same  nomenclature  used  for 
NPSLE.  All  the  NBD  patients  met  these  criteria.  In  particular, 
regarding headache, the patients who responded to conventional 
medication and had other explainable causes were excluded due 
to some discrepancy in the relationship between headache and 
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* Demographics NPSLE  (n=25) NBD  (n=18) p
Gender  (male/female),  number
Age  at  neuropsychiatric  event,  years
Disease  duration  prior  to  neuropsychiatric  attack,  months
Follow‐up  duration,  months
3/22
31±10
50±55
42±36
11/7
38±9
36±26
36±15
0.001
0.024
0.644
0.166
*The  data  is  presented  as  means±standard  deviations  (SD)  except f o r  g e n d e r .  
Table  1.  Demographic  data  for  the  neuropsychiatric  SLE  (NPSLE)  and  neuroBehçet’s  disease  (NBD)  patients
As the part of the initial evaluation, all the patients underwent 
routine  laboratory  tests,  chest  radiographs  and  electrocar-
diograms.  The  sera  of  the  NPSLE  patients  were  tested  for 
antinuclear antibodies, the C3 and C 4 complement components, 
antibodies  to  extractable  nuclear  antigens,  antibodies  to 
double-stranded  DNA  as  assessed  by  radioimmunoassay,  and 
anticardiolipin  antibodies  (ACA)  and  anti-β2  -glycoprotein  I 
antibodies  (anti  β2-GPI  antibodies)  as  assessed  by  ELISA. 
Positive levels of ACA and anti β2-GPI antibodies were defined 
as  being  levels  >  5  standard  deviations  above  the  mean  levels 
of  100  healthy  controls.  Where  indicated,  some  of  the  patients 
underwent  cerebrospinal  fluid  analysis,  electroencephalograms 
and  echocardiograms.
Each patient was treated differently, according to their disease 
severity  and  possible  causes.  Treatment  was  classified  as  1) 
conservative  therapy,  which  was  composed  of  neurological  or 
psychiatric  regimens,  and  2)  immune  suppressive  therapy  with 
high  dose  oral  prednisolone  (1-2  mg/kg/day)  and/or  other 
immunosuppressive  agents  that  included  cyclophosphamide, 
azathioprine, chlorambucil, methotrexate, cyclosporine, interferon-
α  (IFN-α)  and  anti-tumor  necrosis  factor-α  (anti-TNF-α).  The 
treatment response and clinical course, that is, episodic (a single 
episode  of  neuropsychiatric  manifestations),  remittent  (recurrent 
episodes  of  remission  and  relapse  of  neuropsychiatric  manifes-
tations), and sustained or progressive (persistent neuropsychiatric 
manifestations  without  remission),  were  also  analyzed  in  each 
patient.  The  treatment  response  was  classified  into  a  good, 
partial and poor response. A good response was defined as the 
complete  improvement  of  neuropsychiatric  symptoms  without 
any  sequela.  A  partial  response  was  defined  as  the  initial 
improvement  with  later  exacerbation  and/or  incomplete 
improvement with sequela. A poor response was defined as no 
improvement  and/or  exacerbations.
Brain  magnetic  resonance  imaging  (MRI)
All the patients underwent brain MRI to determine the causes 
of  their  neuropsychiatric  symptoms,  and  the  MRI  included 
T1-wighted  images,  T2-weighted  images  and  fluid-attenuated 
inversion-recovery (FLAIR) images. The MRI was performed using 
a  1 . 5  T  M R I  s y s t e m  ( G E  S I G N A  A d v a n t a g e  v e r s i o n  4 . 8 ) .  T h e  
conventional spin echo pulse sequence with a TE of 20 ms and 
a  TR  of  400  ms  was  used  to  obtain  the  T1-weighted  MR 
images. The fast spin echo pulse sequence with a TE of 90 ms 
and a TR of 2,500 ms was used to obtain the T2-weighted MR 
images.  Contrast  medium  was  administered  to  all  patients,  and 
t h i s  w a s  f o l l o w e d  b y  o b t a i n i n g  t h e  a x i a l / s a g i t t a l / c o r o n a l  
T1-weighted  images.  Two  neuroradiologists,  who  were unaware 
of  the  clinical  data,  evaluated  the  MRI.  For  analysis,  the 
abnormal MRI findings were carefully classified into the following 
categories:  an  abnormal  T2  weighted  image,  infarct-like  lesions 
(moderate-size  to  large,  roughly  wedge-shaped  areas  of 
abnormal  high  signal  on  the  T2-weighted  images  and/or 
encephalomalacia  involving  the  gray  and  white  matter), 
parenchymal  hemorrhage,  loss  of  brain  volume,  abnormal 
intracranial  enhancement  and  meningeal  enhancement.  The 
location of the brain lesions was also analyzed. The lesions were 
classified  as  stable,  resolving  or  progressing  if  the  patients 
underwent  MRI  more  than  once.
Statistical  analysis
Comparisons of the numerical data between the groups were 
performed  using  the  Mann-Whitney  rank  sum  test,  and  the 
categorical data was analyzed using chi-square tests or Fisher's 
exact  probability  tests.  p  values  <  0.05  were  considered  to  be 
significant. 
RESULTS
Demographic  and  extra-neuropsychiatric  features
The  demographic  characteristics  of  the  43  patients  (25 
NPSLE patients and 18 NPBS patients) are summarized in Table 
1.  The  NPSLE  patients  showed  a  female  predominance 
(p=0.001). The age at the time of the neuropsychiatric event was 
h i g h e r  f o r  t h e  N B D  p a t i e n t s  ( 3 8 ± 9  y e a r s )  t h a n  f o r  t h e  N P S L E  
patients (31±10 years) (p=0.024). The disease duration pri or to 
t h e  n e u r o p s y c h i a t r i c  a t t a c k  a n d  t h e  l e n g t h  o f  t h e  f o l l o w - u p  
period was similar for the two groups. For the NPSLE, 3 patients 
(12.0%) had antiphospholipid syndrome, 7 patients (28.0%) had 
lupus  nephritis,  2  patients  (8.0%)  had  mesenteric  vasculitis  and 
5 patients (20.0%) had hematological abnormalities that affected 
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*  Neuropsychiatric  manifestations NPSLE NBD p
Mood  disorder
    Major  depression
  D e p r e s s i v e  f e a t u r e s
    Manic  features
  M i x e d  f e a t u r e s
Psychosis
Acute  confusional  states
Cognitive  dysfunction
Seizure 
    Generalized
    Partial
Headache
  M i g r a i n e
  T e n s i o n
  C l u s t e r
    Pseudotumor  cerebri
    Nonspecific
Cerebrovascular  disease
  S t r o k e
    Transient  ischemic  attack
  M u l t i f o c a l  d i s e a s e
    Intracranial  hemorrhage
    Sinus  thrombosis
Neuropathy,  cranial
Aseptic  meningitis
Myelopathy
Demyelinating  syndrome
Mononeuropathy
Polyneuropathy
Movement  disorder
8  (32.0)
3
3
2
0
1  (4.0)
2  (8.0)
3  (12.0)
8  (32.0)
5
3
3  (12.0)
0
2
0
0
1
5  (20.0)
3
0
1
1
0
1  (4.0)
2  (8.0)
2  (8.0)
1  (4.0)
1  (4.0)
1  (4.0)
1  (4.0)
3  (16.7)
1
2
0
0
0  (0)
0  (0)
8  (44.4)
3  (16.7)
2
1
7  (38.9)
4
3
0
0
0
2  (11.1)
2
0
0
0
0
6  (33.3)
1  (5.6)
1  (5.6)
0  (0)
0  (0)
0  (0)
1  (5.6)
0.309
1.000
0.502
0.031
0.309
0.067
0.680
0.015
1.000
1.000
1.000
1.000
1.000
1.000
*  The  data  is  presented  as  the  number  (%)  of  events. 
Table 2. Comparison of the neuropsychiatric manifestations between the neuropsychiatric SLE (NPSLE) and neuroBehçet’s disease (NBD) patients
according  to  the  ACR  case  definitions  for  NPSLE
recurrent  oral  ulcerations,  7  patients  (38.9%)  had  genital 
ulcerations,  8  patients  (44.4%)  had  eye  lesions,  15  patients 
(83.3%)  had  skin  lesions  such  as  erythema  nodosum  and 
folliculitis,  1  patient  had  gastrointestinal  involvement,  8  patients 
(44.4%)  had  arthritis  and  1  patient  had  major  arterial 
involvement.
Neuropsychiatric  manifestations
Table 2 shows the neuropsychiatric manifestations in the two 
groups.  As  initial  manifestations,  the  neuropsychiatric  complica-
tions were the major symptoms and signs in 5 SLE patients and 
3  Behet's  disease  patients.  Four  NPSLE  patients  and  4  NBD 
patients had a history of previous neuropsychiatric complications. 
These  include  mononeuritis  multiplex,  seizure  and  transverse 
myelitis  for  the  NPSLE  patients,  and  aseptic  meningitis, 
cerebrovascular disease (CVD) and cognitive dysfunction for the 
NBD patients. Sixteen (64.0%) NPSLE patients showed evidence 
of  concomitant  extra-neuropsychiatric  complications  (e.g.  lupus 
nephritis and mesenteric vasculitis) and/or elevated SLE activity, 
which  was  determined  by  the  levels  of  C3,  C4 a n d  t h e  
anti-double-stranded  DNA  antibody.
The  common  features  in  the  NPSLE  patients  were  mood 
disorders  (32.0%),  seizure  (32.0%),  and  CVD  (20.0%).  In 
contrast,  the  common  features  in  the  NBD  patients  were 
cognitive  dysfunction  (44.4%),  headache  (38.9%),  and  cranial 
neuropathy  (33.3%).  Cognitive  dysfunction  and  cranial 
n e u r o p a t h y  w e r e  m o r e  c o m m o n  i n  t h e  N B D  p a t i e n t s .  A l l  t h e  
patients  with  cognitive  dysfunction  in  both  groups  were 
associated  with  a  variety  of  neurologic  or  psychiatric  diseases, 
including  neuropathy,  headache,  CVD,  movement  disorder  and 
mood  disorders.  Half  of  the  cranial  neuropathy  of  the  NBD 
patients (3 of 6) was associated with cognitive dysfunction. The 
types of cranial neuropathy of the NBD patients were vestibule- 
cochlear  dysfunction  (4  of  6  patients)  and  oculomotor 
dysfunction (2 of 6 patients). One NPSLE patient had optic nerve 
dysfunction.
I mpor t a n t l y ,  Ta bl e  3 s howe d t he  s u bgr ou p a na l y s i s ,  a nd t h i s 
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* Neuropsychiatric  manifestations NPSLE  (n=25) NBD  (n=18) p
Diffuse  disease
Focal  disease
Complex  disease
14  (56.0)
 8  ( 3 2 . 0 )
 3  ( 1 2 . 0 )
3  (16.7)
9  (50.0)
6  (33.3)
0.013
0.234
0.133
*  The  data  is  presented  as  the  number  (%)  of  events.
Table  3.  Subgroup  analysis  of  the  neuropsychiatric  manifestations
*Brain  MRI  findings NPSLE  (n=25) NBD  (n=18) p
MRI  abnormalities
    Abnormal  T2  weighted  image
  I n f a r c t  l i k e  l e s i o n s
    Parenchymal  hemorrhage   
  V o l u m e  l o s s
    Abnormal  intracranial  enhancement
    Meningeal  enhancement
  N e g a t i v e
15  (60)
  4  (16)
 2  ( 8 )
  4  (16)
  5  (20)
  3  (12)
  8  (32)
15  (83.3)
 3  ( 1 6 . 7 )
 0  ( 0 )
 3  ( 1 6 . 7 )
 3  ( 1 6 . 7 )
 0  ( 0 )
 3  ( 1 6 . 7 )
0.178
1.000
0.502
1.000
1.000
0.252
0.309
Location  of  lesions
    Cerebral  white  matter
    S u b c o r t e x
    D e e p  w h i t e  m a t e r
        Periventriclular
  B a s a l  g a n g l i a
  I n t e r n a l  c a p s u l e
  T h a l a m u s
    Brain  stem
    P o n s
        Mid  brain
    M e d u l l a
    Cerebellum
  M e n i n g e s
  S p i n a l  c o r d
11  (48)
  8  (32)
  5  (20)
 2  ( 8 )
  6  (24)
 1  ( 4 )
 2  ( 8 )
  5  (20)
  3  (12)
  3  (12)
 1  ( 4 )
  3  (12)
  3  (12)
 1  ( 4 )
 4  ( 2 2 . 2 )
 3  ( 1 6 . 7 )
  1  (5.6)
 0  ( 0 )
 6  ( 3 3 . 3 )
  1  (5.6)
 2  ( 1 1 . 1 )
10  (55.6)
 6  ( 3 3 . 3 )
 7  ( 3 8 . 9 )
 0  ( 0 )
 2  ( 1 1 . 1 )
 0  ( 0 )
  1  (5.6)
0.115
0.309
0.375
0.502
0.516
1.000
1.000
0.024
0.133
0.067
1.000
1.000
0.252
1.000
*  The  data  is  presented  as  the  number  (%).
Table  4. C o m p a r i s o n  o f  t h e  b r a i n  M R I  f i n d i n g s  i n  t h e  n e u r o p s y c h i a t r i c  S LE  (NPSLE)  patients  and  the  neuroBehçet’s  disease  (NBD)  patients
NPSLE patients (56.0 versus 16.7%, respectively, p=0.013). The 
frequency  of  focal  manifestations  and  complex  manifestations 
was  similar  for  both  groups. 
All  the  NPSLE  patients  underwen t  t e s t s  f o r  t h e  A C A  a n d / o r  
anti 2-GPI antibodies. A minimum of 2 positive tests (either ACA 
and/or  anti  2-GPI  antibodies)  were  required  before  the  patient 
was confirmed to be positive for anti-phospholipid antibody. The 
result  showed  that  13  NPSLE  patients  (52.0%)  had  increased 
levels of the anti-phospholipid antibody with a high titer (> 5 SD 
over  the  mean  levels  of  the  healthy  controls);  7  patients  were 
positive  for  ACA  and  13  patients  tested  positive  for  anti  2-GPI 
antibodies, respectively. Three of 8 patients with seizure disorder 
had  increased  levels  of  ACA  and  anti  2-GPI  antibodies.  In 
addition,  2  of  5  patients  with  CVD  and  all  3  patients  with 
cognitive  dysfunction  tested  positive  for  anti-  phospholipid 
antibody.  The  other  neuropsychiatric  features  that  were 
associated  with  a  positive  test  for  anti-phospholipid  antibody 
included  mood  disorders,  acute  confusional  states,  psychosis, 
transverse  myelitis,  cranial  neuropathy  and  movement  disorders.
MRI  findings
A s  s h o w n  i n  T a b l e  4 ,  t h e  N B D  a n d  N P S L E  p a t i e n t s  h a d  
different  predilections  of  brain  lesions.  For  example,  the  brain 
stem  lesions  on  MRI  were  more  frequently  encountered  in  the 
NBD patients (55.6 versus 20.2%, respectively, p=0.024), whereas 
the frequency of the cerebral white matter abnormalities tended 
t o  b e  h i g h e r  i n  t h e  N P S L E  p a t i e n t s  t h a n  i n  t h e  N B D  p a t e n t s  
(44.0  versus  22.2%,  respectively)  (Table  4,  Figure  1). 
Abnormalities in the cerebral white matter of the NPSLE patients 
were  mainly  located  in  the  frontal  and  parietal  lobes. 
I t ' s  i nt e r e s t i n g t ha t  8 ( 32. 0%)  of  t he  25 NP SLE pa t i e n t s  a nd 
3  (16.7%)  of  the  18  NBD  patients  had  a  normal  brain  MRI, 
despite having definite neuropsychiatric symptoms and signs. Of 
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Figure 1. Representative MRI findings in a neuroBehçet’s disease (NBD) patient and a
neuropsychiatric  SLE  (NPSLE)  patient.  (A)  Fluid-attenuated  inversion-  recovery  (FLAIR) 
images of a 43-year-old male NBD patient with cranial neuropathy. There are abnormal
s i g n a l s  i n  t h e  b r a i n  s t e m  a n d  t h e  l e f t  f r o n t a l  w h i t e  m a t t e r .  ( B )  FLAIR  images  of  a 
15-year-old female NPSLE patient with generalized seizure. There are abnormal signals
in  the  subcortical  and  periventricular  white  matter.
neuropsychiatric manifestations as their major symptom, whereas 
all  3  NBD  patients  presented  with  focal  manifestations  such  as 
seizure and movement disorders. Parenchymal volume loss was 
observed  in  4  NPSLE  and  3  NBD  patients.  An  abnormal  high 
signal  was  typically  high  on  the  FLAIR  and  other  T2-weighted 
images,  and  this  was  observed  in  15  (60.0%)  NPSLE  patients 
and  15  (83.3%)  NBD  patients.  However,  this  was  frequently 
nonspecific,  and  this  was  interpreted  as  being  consistent  with 
focal  ischemia,  demyelination  or  vasculitis.  Infarct-like  lesions 
w e r e  o b s e r v e d  i n  4  N P S L E  p a t i e n t s  a n d  3  N B D  p a t i e n t s .  
Parenchymal  hemorrhage  was  observed  in  only  2  NPSLE 
patients.  Five  NPSLE  patients  and  3  NBD  patients  showed 
abnormal  intracranial  enhancement,  mainly  with  focal  and 
heterogonous  distributions.  Other  minor  abnormalities  included 
meningeal  contrast  enhancement  in  the  NPSLE  patients,  and 
internal  carotid  artery  narrowing,  venous  angioma,  lipoma  and 
me g a  c i s t e r n a  ma g n a t a  i n  t h e  N B D  p a t i e n t s .  
The follow-up MRI, taken at an interval of from 1 month to 2 
years, was avai lable for 7 NPSLE patients and 3 NBD patients. 
For  the  NPSLE  patients,  two  showed  complete  regression,  two 
showed  partial  regression,  two  showed  progression  and  one 
showed  no  change.  For  the  NBD  patients,  two  showed 
regression and one did not  show  any  change  on the follow-up 
MRI.
Therapy  and  clinical  course
Table  5  and  Figure  2  show  the  therapy,  treatment  response 
and  clinical  course  of  the  patients. The  maintenance therapy  of 
all  the  patients  included  prednisolone  at  the  time  of  the  attack 
for  treating  a  variety  of  causes.  The  percentage  of  patients 
receiving  conservative  or  immune  suppressive  therapy  was  not 
significantly  different  between  the  NPSLE  patients  and  NBD 
patients  (e.g.  conservative  treatment:  32.0%  for  the  NPSLE 
p a t i e n t s  a n d  2 2 . 2 %  f o r  t h e  N B D  p a t i e n t s ) .  A f t e r  t h e  
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*Characteristics NPSLE  (n=25) NBD  (n=18) p
Treated  with
**Cyclophosphamide 
  A z a t h i o p r i n e
    Methotrexate
  C y c l o s p o r i n e
    Chlorambucil
  I n t e r f e r o n - α
    Anti-tumor  necrosis  factor-α
6  (24)
1  (4)
1  (4)
0  (0)
0  (0)
0  (0)
0  (0)
1  (5.6)
5  (27.8)
0  (0)
 4  ( 2 2 . 2 )
 2  ( 1 1 . 1 )
1  (5.6)
1  (5.6)
0.209
0.067
1.000
0.025
0.169
0.419
0.419
Number  of  second‐line  drugs
  ≥ 4
  ≥ 3
  ≥ 2
  ≥ 1
0  (0)
1  (4) 
5  (24)
17  (68)
1  (5.6)
2  (11.1)
4  (22.2)
14  (77.8)
0.419
0.562
1.000
0.481
*  The  data  is  presented  as  the  number  (%).
**  Intravenous,  0.75–1.0  g/m
2  body  surface  area,  monthly.
Table  5.  Comparison  of  the  immune  suppressants  newly  added  and  maintained  after  neuropsychiatric  attack  in  the  neuropsychiatric  SLE  (NPSLE)
and  neuroBehçet’s  disease  (NBD)  patients
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Figure  2. Comparison  of the initial treatment  response (A) and disease 
course  (B)  after  conservative  or  immune  suppressive  treatment  for 
neuropsychiatric  SLE  (NPSLE)  and  neuroBehçet’s  disease  (NBD) 
patients.  The  data  is  presented  as  a  percentage.  *,  p <  0 . 0 5 ;  * * ,  p <  
0.01.
neuropsychiatric  attack,  16  NPSLE  patients  (64%)  and  7  NBD 
patients (38.9%) were given high dose oral prednisolone therapy 
(1-2  mg/kg/day)  (p=0.766).  Among  them,  8  NPSLE  patients 
(32%)  and  5  NBD  patients  (27.8%)  were  given  intravenous 
m e t h y l p r e d n i s o l o n e  p u l s e  t h e r a p y  ( 5 0 0  m g - 1 g  d a i l y  f o r  t h r e e  
days) (p=0.153). The number and type of immune suppressants 
(e.g.  cyclophosphamide,  azathioprine)  that  were  newly  added 
and then maintained after the neuropsychiatric attack was similar 
i n  t h e  t w o  g r o u p s  w i t h  c y c l o s p o r i n e  b e i n g  t h e  o n l y  e x c e p t i o n  
(Table  5).  Three  NPSLE  patients  with  anti-  phospholipid 
syndrome were also treated with an anticoagulant. Three NPSLE 
patients with intractable thrombocytopenia or thrombotic throm- 
bocytopenic  purpura  were  treated  with  high  dose  prednisolone 
plus  intravenous  immunoglobulin  and/or  plasmapheresis.  Two 
NBD  patients  (one  with  CVD  and  one  with  cranial  neuropathy 
along with cognitive dysfunction) had progressive disease despite 
being  treated  with  high  dose  prednisolone  plus  immune 
suppressants.  Therefore,  biological  agents  such  as  IFN-  and 
anti-TNF-  monoclonal  antibody  were  added  to  the  above- 
mentioned  immune  suppressants  for  treating  these  2  patients.
For  most  patients,  the  neuropsychiatric  manifestations 
improved  after  being  treated  with  conservative  or  immune 
suppressive  treatments  (88.0%  for  the  NPSLE  patients  and 
88.9%  for  the  NBD  patients)  (Figure  2A).  However,  the  disease 
course  was  significantly  different  between  the  two  groups  after 
the  initial  improvement.  Episodic  cases  were  more  common  in 
the NPSLE patients (65.0 versus 22.2%, respectively,  p=0.012), 
while  remittent  cases  were  more  frequently  noted  in  the  NBD 
patients  (72.2  versus  24.0%,  respectively,  p=0.02)  (Figure  2B). 
Two NBD patients showed a good or partial response with the 
additional  IFN-  or  anti-TNF-  monoclonal  antibody  treatment. 
However,  the  biological  agents  failed  to  prevent  further  attacks 
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or progression of disease. The number of patients who showed 
a sustained or progressive course that was refractory to therapy 
was  similar  in  the  two  groups. 
DISCUSSION
Systemic  immune-mediated  diseases  can  often  affect  the 
nervous  system
12, 13),  and  among  them,  SLE  and  Behçet's 
disease  are  the  common  autoimmune  diseases  of  the  nervous 
system  in  Korea.  NPSLE  is  believed  to  have  a  particular 
propensity  to  cause  diffuse  manifestations  or  psychiatric 
disorders
14). In contrast, NBD is commonly associated with CNS 
parenchyma  and  central  venous  sinus  thrombosis,  and  it  rarely 
presents  as  psychiatric  disorders
4).  However,  no  trial  has  been 
carried  out  to  compare  the  two  diseases,  even  though  both 
conditions  have  been  associated  with  immune-mediated 
mechanisms  and  they  have  pathologically  revealed  small  vessel 
vasculopathy  in  the  parenchyma  of  the  nervous  system.  The 
classic  histopathological  studies  of  the  nervous  system  in  SLE 
patients  have  shown  vascular  changes  and  the  resultant 
microinfarts, although any true vasculitis was rare
14). As for NBD, 
vasculitis is believed to be the underlying pathological process of 
Behçets  disease  and  the  pattern  of  the  parenchymal  lesions 
seen  on  cranial  MRI  was  consistent  with  small  vessel  vasculitis 
and  inflammation  of  veins.  However,  there  are  contradictory 
reports  on  the  observed  pathology  and  the  observed 
histopathologic  changes  cover  a  wide  spectrum,  including 
v a s c u l t i s ,  l o w  g r a d e  i n f l a m m a t i o n ,  d e m y e l i n a t i o n  a n d  
degenerative changes. Definite vasculitis has not been observed 
in  all  cases
13).  Our  current  study  was  performed  in  a  single 
hospital,  and  it  showed  that  the  NPSLE  patients  had  a  female 
predominance,  and  they  were  generally  younger  than  the  NBD 
patients.  In  addition,  the  NPSLE  patients  had  a  greater 
propensity for diffuse manifestations than the NBD patients, even 
though  the  possibility  of  a  referral  bias  cannot  be  completely 
ruled  out.  There  is  a  serious  doubt  regarding  the  previously 
suggested  relationship  between  headache  and  SLE
7),  whereas 
headache  is  considered  the  most  common  neurological 
symptom  observed  in  Behçet's  disease  patients
4).  In  contrast, 
the  frequency  of  focal  diseases  such  as  cranial  neuropathy  or 
headache  tended  to  be  higher  in  the  NBD  patients.  These 
findings  show  a  different  pattern  of  neuropsychiatric 
p r e s e n t a t i o n s  b e t w e e n  t h e  N P S L E  a n d  N B D  p a t i e n t s ,  a n d  t h e y  
suggest that NPSLE might be caused by a different immunologic 
process  from  NBD.
T h e  m a i n  p r o b l e m  i s  h o w  t o  p l a u s i b l y  e x p l a i n  t h i s  
discrepancy.  The  spectrum  of  the  syndromes  seen  in  NPSLE 
and  NBD  patients  probably  reflects  multiple  pathological 
processes, but ischemia is widely accepted to play a major role 
in causing CNS disorders in SLE patients, and reperfusion of an 
ischemic  area  carries  the  risk  of  edema  and  hemorrhage
15, 16). 
The  wide  range  of  antibodies  is  a  distinctive  immunological 
feature of SLE, which is in contrast to Behçet's disease. These 
autoantibodies  are  believed  to  play  two  different,  but  not 
mutually  exclusive  roles  in  mediating  neurological  injury;  direct 
injury to the neural target cells and antibody-induced rheological 
disturbances leading to an infarction
14). Of the two mechanisms, 
antibody-mediated  diffuse  neural  damage  might  be  a  possible 
mechanism  for  the  propensity  of  NPSLE  patients  to  exhibit 
diffuse  manifestations,  while  antibody-induced  rheological 
disturbances  are  widely  accepted  to  be  the  major  event  for 
causing  CVD.  In  this  study,  the  high  prevalence  (52%)  of 
anti-phospholipid  antibodies  with  a  high  titer  in  the  NPSLE 
patients  supports  this  hypothesis.
MRI  is  a  useful  tool  for  detecting  CNS  lesions  in  patients 
suffering  with  SLE  and  Behçet's  disease
17, 18).  Up  to  70%  of 
NPSLE patients have multiple white matter lesions seen on brain 
MRI
18).  The  lesions  appear  on  the  T2  images  as  high  signal 
areas  in  the  periventricular  and  subcortical  white  matter,  and 
they  usually  appear  as  normal  in  the  T1-weighted  images
17). 
Neuro-imaging  studies  on  NBD  patients  have  shown  that  these 
lesions  are  generally  located  within  the  brain  stem,  occasionally 
with an extension to the diencephalons, or less commonly within 
the  periventricular  and  subcortical  white  matter
4, 18).  These 
lesions  are  generally  observed  as  high  signal  intensity  on  the 
T2-weighed  images
18).  T h i s  c u r r e n t  s t u d y  a l s o  s h o w e d  d i f f e r e n t  
predilections  of  MRI  involvement  in  the  NPSLE  patients  versus 
the  NBD  patients,  which  is  consistent  with  earlier  reports
4, 17-19). 
The  lesion  predilection  for  the  brain  stem  together  with  the 
sparseness of cortical lesions might explain the rarity or lack of 
higher  cortical  function  disturbances  in  the  NBD  patients.  The 
reason for the lesion predilection in the brain stem, basal ganglia 
and diencephalons is not known. It has been hypothesized that 
inflammation of the small-to-medium sized veins of those regions 
might be responsible for causing venous infarcts
20). Although this 
appears to be reasonable, more pathological studies are needed 
to  support  this  hypothesis. 
I n  t h i s  s t u d y ,  8  ( 3 2 % )  o f  t h e  2 5  N P S L E  p a t i e n t s  a n d  3  
(16.7%)  of  the  18  NBD  patients  had  a  normal  MRI,  despite 
having definite neuropsychiatric complications. Of note, 5 of the 
8 NPSLE patients with a normal MRI had diffuse manifestations. 
A neuroneolytic effect of the antibodies in SLE patients would be 
d i f f i c u l t  t o  r e c o n c i l e  w i t h  t h e  t r a n s i e n t  n a t u r e  o f  m a n y  o f  t h e  
neurological  features,  as  well  as  with  the  absence  of  clear 
pathological  changes  of  the  selective  neuronal  cell  loss.  One 
possibility would be the presence of non-lethal autoantibodies in 
the  SLE  patients,  which  could  elicit  a  transient  alteration  of  the 
cell  function  without  causing  cell  death  or  inflammation.  This 
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abnormalities  in  many  SLE  patients  who  have  diffuse 
p r e s e n t a t i o n s .  I n  p a r a l l e l  w i t h  t h i s  h y p o t h e s i s ,  a  m o r e  s e n s i t i ve 
imaging  tool  such  as 
1H  magnetic  resonance  spectroscopy  is 
currently being introduced to detect the neuometabolite changes 
that  precede  permanent  neuronal  loss
21).
The  treatment  for  NPSLE  and  NBD  should  be  adjusted 
according  to  the  requirements  of  the  individual  patient  because 
the neurological involvement in SLE and Behcet's disease is not 
uniform
4, 22). Symptomatic, immunosuppressive and anticoagulant 
therapies are the main strategies for managing NPSLE and NBD. 
In  this  study,  the  neuropsychiatric  manifestations  were  at  least 
partially improved in almost all patients of both groups. However, 
the prognosis was significantly different between the patients  of 
the  two  groups.  The  NBD  patients,  who  showed  a  good 
response initially, they  tended to be remittent, while the NPSLE 
patients  tended  to  be  episodic.  This  discrepancy  suggests  that 
NBD should be treated more aggressively in order to prevent its 
recurrence  or  progression.  Unfortunately,  there  is  little  evidence 
on  the  efficacy  of  various  treatment  modalities  for  any  form  of 
neurological  treatment  in  Behçet's  disease
4).
  Biological  agents, 
including  the  IFN-antibody  and  anti-TNF-α  antibody,  have 
recently  been  anecdotally  reported  to  be  of  benefit  for  treating 
some  of  the  systemic  manifestations  of  Behçet's  disease. 
However, none of these agents have been shown to be effective 
in  a  properly  designed  study
4).  In  this  study,  the  IFN-α  or 
anti-TNF-α antibody failed to prevent further neurological attacks 
or  progression  in  the  two  NBD  patients.
T h i s  r e p o r t  i s  t h e  f i r s t  t o  d e s c r i b e  t h e  c l i n i c a l  f i n d i n g s ,  b r a in 
MRI  and  prognosis  of  NPSLE  patients  and  NBD  patients  in  a 
single  hospital.  The  differences  in  neuropsychiatric  presen-
tations, the location of the brain lesions on MRI and the clinical 
course between the NPSLE patients and NBD patients suggest 
that  there  might  be  a  different  pathological  process  involved  in 
each disease, and these 2 diseases should be treated differently 
in  order  to  prevent  recurrent  attacks  or  progression  of  disease. 
However,  this  study  was  limited  by  its  retrospective  nature  and 
the small number of subjects. Prospective multi-center trials are 
needed  to  provide  more  clues  for  understanding  the  diseases' 
pathogenetic  mechanisms,  to  guide  further  research  on  their 
cause  and  to  find  more  effective  treatments  for  these  serious 
and  potentially  life-threatening  diseases. 
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